Achievement of Treat-to-Target Thresholds with Envudeucitinib, a Selective TYK2 Inhibitor, in Moderate-to-Severe Plaque Psoriasis: Results from STRIDE and OLE. (2025). SKIN The Journal of Cutaneous Medicine, 9(6), s650. https://doi.org/10.25251/8xwzce61